Edition:
United Kingdom

UCB Granted Orphan Drug Designation For Treatment Of Intermittent Bouts Of Increased Seizure Activity


Monday, 13 Aug 2018 

Aug 13 (Reuters) - UCB SA ::GRANTED ORPHAN DRUG DESIGNATION FOR TREATMENT OF INTERMITTENT BOUTS OF INCREASED SEIZURE ACTIVITY.GRANTED ORPHAN DRUG DESIGNATION FOR TREATMENT OF INTERMITTENT BOUTS OF INCREASED SEIZURE ACTIVITY.MIDAZOLAM NASAL SPRAY HAS ALSO BEEN GRANTED FAST TRACK DESIGNATION BY THE US FDA DUE TO THE HIGH UNMET NEED FOR PATIENTS AND CAREGIVERS.MIDAZOLAM NASAL SPRAY HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (US FDA) .